Monoclonal antibodies for difficult-to-treat multiple myeloma

At the 42nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), held in Valencia, Spain, EBMT 2016 President Mohamad Mohty, MD, PhD, from Saint-Antoine Hospital, Paris, France, discusses the EBMT session focussing on difficult-to-treat patients in four diseases: multiple myeloma, mantle cell lymphoma, chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). Sessions involved a state-of-the-art lecture on the use of monoclonal antibodies in the field of multiple myeloma, highlighting two new monoclonal antibodies: elotuzumab, which targets SLAMF7 and daratumumab, which targets CD38.